Caris Life Sciences is featured in the latest Newsweek feature/cover story. The article provides an overview of the current state of precision oncology (growing interest and abilities, but underutilized), addresses challenges (doctors lacking expertise in the area and expense/reimbursement issues, clinical trial enrollment for new drugs) and also highlights opportunities – with a keen focus on the ability of AI to accelerate precision oncology.
David H. Freedman
By Targeting Each Patient’s Unique Tumor, Precision Medicine Is Crushing Once-Untreatable Cancers. But Only a Fraction of Patients Currently Benefit. Can Medicine Close the Gap?